Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
304.00
-10.00 (-3.18%)
At close: Jan 21, 2026
17.83%
Market Cap79.95B
Revenue (ttm)18.66B
Net Income (ttm)4.73B
Shares Out262.98M
EPS (ttm)18.04
PE Ratio16.85
Forward PE11.87
Dividend5.78 (1.84%)
Ex-Dividend DateAug 11, 2025
Volume5,363,474
Average Volume4,130,655
Open315.50
Previous Close314.00
Day's Range302.50 - 317.00
52-Week Range172.50 - 344.50
Beta0.20
RSI53.96
Earnings DateMar 4, 2026

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business... [Read more]

Sector Healthcare
Founded 1966
Employees 1,099
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1795
Full Company Profile

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.

Financial Statements